Santiago Madera, María F Chervo, Violeta A Chiauzzi, Matías G Pereyra, Leandro Venturutti, Franco Izzo, Agustina Roldán Deamicis, Pablo Guzman, Agustina Dupont, Juan Carlos Roa, Mauro E Cenciarini, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Teresa Castiglioni, Eduardo Cortese, Sandra Ares, Ernesto Gil Deza, Felipe G Gercovich, Cecilia J Proietti, Roxana Schillaci, Rosalía I Cordo Russo, Patricia V Elizalde
The hormone receptor-positive (estrogen and/or progesterone receptor (PR)-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that includes luminal A-like (LumA-like) and luminal B-like (LumB-like) subtypes. Decreased PR levels is a distinctive biological feature of LumB-like tumors. These tumors also show reduced sensitivity to endocrine therapies and poorer prognosis than LumA-like tumors. Identification of biomarkers to accurately predict disease relapse in these subtypes is crucial in order to select effective therapies...
July 6, 2020: Hormones & Cancer